002262 恩华药业
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)15.03917.20217.08817.64318.824
总资产报酬率 ROA (%)13.19915.01814.79215.27516.287
投入资产回报率 ROIC (%)14.45116.69616.59817.17318.498

边际利润分析
销售毛利率 (%)73.75372.82976.26077.20075.542
营业利润率 (%)28.25723.45223.34423.52525.470
息税前利润/营业总收入 (%)27.50622.79822.54623.00324.588
净利润/营业总收入 (%)24.52220.51520.47420.27721.632

收益指标分析
经营活动净收益/利润总额(%)99.75396.64994.92898.28597.462
价值变动净收益/利润总额(%)3.7644.3683.6643.9562.527
营业外收支净额/利润总额(%)-1.648-1.172-1.370-1.102-0.665

偿债能力分析
流动比率 (X)6.3796.4555.8575.9295.774
速动比率 (X)5.6675.6834.9555.0435.019
资产负债率 (%)12.60612.52813.84713.9270.135
带息债务/全部投入资本 (%)3.2661.6490.8500.9380.493
股东权益/带息债务 (%)2,923.2095,869.33511,456.12810,330.36719,840.843
股东权益/负债合计 (%)695.996700.820626.404620.161641.270
利息保障倍数 (X)-93.718-59.674-46.628-86.642-34.455

营运能力分析
应收账款周转天数 (天)75.50766.25162.70757.73661.037
存货周转天数 (天)159.993176.733232.955208.257170.637